NHAI Terminates Arakkonam-Kancheepuram Builder Contract for Bengaluru-Chennai Expressway
Quick Brief
The National Highways Authority of India (NHAI) has officially canceled the construction contract for the Arakkonam-Kancheepuram section of the Bengaluru-Chennai Expressway. To finish the remaining construction, new tenders have been issued under the engineering, procurement, and construction (EPC) mode.
What Happened?
The NHAI terminated the agreement with the builder responsible for the Arakkonam-Kancheepuram stretch of the Bengaluru-Chennai Expressway. Following the termination, fresh tenders worth ₹633.12 crore were floated to finish the uncompleted tasks.
Why It Matters
Contract terminations on major infrastructure corridors can lead to scheduling delays, making the re-tendering process critical for keeping the Bengaluru-Chennai Expressway project moving forward.
Key Facts
- The NHAI canceled the contract for the Arakkonam-Kancheepuram builder on the Bengaluru-Chennai Expressway.
- Fresh tenders have been floated to complete the remaining project work.
- The new work is estimated to cost ₹633.12 crore.
- The replacement project is slated to be completed within 18 months.
- The new procurement will operate under the engineering, procurement and construction (EPC) mode.
What Happens Next?
The remaining construction work will be executed under the newly floated EPC mode tenders within a timeline of 18 months.
Compiled from 1 outlet
Related Stories
Malabar Milma Approves ₹1.72 Crore Subsidy for Cattle Feed in Keralam
Malabar Milma has sanctioned a ₹1.72 crore subsidy aimed at supporting dairy farmers in Keralam. Through this financial backing, cattle feed will be accessible at reduced prices during September 2026. The initiative is being implemented across all primary dairy cooperative societies within the Malabar region.
Kinder Morgan Files Regulation FD Disclosure with SEC
Kinder Morgan, Inc. has submitted a Form 8-K filing to the U.S. Securities and Exchange Commission. The regulatory filing specifically addresses Item 7.01 concerning Regulation FD Disclosures. The document totals 228 kilobytes in size.
FDA Revokes Drug Sale Licences for Cipla's Pune Facility Over Storage Violations
The food and drug administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences' carry and forwarding unit in Pune. Regulators discovered that pharmaceutical products were being kept directly on the floor. Additionally, authorities identified significant deficiencies in the protocols used for managing expired medicines.
RPG Life Sciences to Acquire Raghava Life Sciences' API Business for ₹135 Crore
RPG Life Sciences is moving to expand its operations by acquiring the active pharmaceutical ingredient (API) and intermediates business of Raghava Life Sciences. The transaction is valued at ₹135 crore. The purchase strengthens RPG Life Sciences' portfolio in the pharmaceutical sector.